Experienced in Age-Related Macular Degeneration (ARMD)

Dr. Daniel V. Zimmer

Ophthalmology
105 Brandt Dr., Suite 201, 
Cranberry Twp., PA 
Experienced in Age-Related Macular Degeneration (ARMD)
105 Brandt Dr., Suite 201, 
Cranberry Twp., PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Zimmer is an Ophthalmologist in Cranberry Twp., Pennsylvania. Dr. Zimmer is rated as an Experienced provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Dry Eye Syndrome, Interstitial Keratitis, Glaucoma, and Conjunctivitis (Pink Eye).

His clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Ophthalmology
Licenses
Ophthalmology in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UPMC
  • EPO
  • PPO
View 2 Less Insurance Carriers -

Locations

105 Brandt Dr., Suite 201, Cranberry Twp., PA 16066

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Betamethasone Sodium Phosphate
Study Phase: Phase 2
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: Combination of Mycophenolic Acid and Betamethasone Sodium Phosphate, Mycophenolic Acid, Restasis Ophthalmic Emulsion, Xiidra Ophthalmic Solution
Study Phase: Phase 2
Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drug: Lotilaner Ophthalmic Solution
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials
Similar Doctors
Jay K. Chhablani
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Jay K. Chhablani
Ophthalmology
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Jay K. Chhablani
Ophthalmology

University Of Pittsburgh Physicians

1300 Oxford Dr, 
Bethel Park, PA 
 (24.2 miles away)
Languages Spoken:
English
See accepted insurances

Jay Chhablani is an Ophthalmologist in Bethel Park, Pennsylvania. Dr. Chhablani is rated as an Elite provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Central Serous Chorioretinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal.

Distinguished in Age-Related Macular Degeneration (ARMD)
Dr. Jose-alain A. Sahel
Ophthalmology
Distinguished in Age-Related Macular Degeneration (ARMD)
Dr. Jose-alain A. Sahel
Ophthalmology

University Of Pittsburgh Physicians

203 Lothrop St, 7th Floor, 
Pittsburgh, PA 
 (18.9 miles away)
412-647-2200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jose-alain Sahel is an Ophthalmologist in Pittsburgh, Pennsylvania. Dr. Sahel is rated as an Elite provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Retinopathy Pigmentary Mental Retardation, Cone-Rod Dystrophy, X-Linked Congenital Stationary Night Blindness, Retinitis Pigmentosa, and Vitrectomy. Dr. Sahel is currently accepting new patients.

Distinguished in Age-Related Macular Degeneration (ARMD)
Dr. Scott D. Pendergast
Ophthalmology
Distinguished in Age-Related Macular Degeneration (ARMD)
Dr. Scott D. Pendergast
Ophthalmology

Retina Associates Of Cleveland, Inc.

170 North Road Northeast, Suite 201, 
Warren, OH 
 (54.2 miles away)
330-856-2238
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Scott Pendergast is an Ophthalmologist in Warren, Ohio. Dr. Pendergast is rated as a Distinguished provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Retinal Detachment. Dr. Pendergast is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zimmer's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile